drugset / Trial / NCT01081431
Safety of Lenalidomide and Markers for Disease Progression in Patients With International Prognostic Scoring System (IPSS) Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) With Isolated del5q
Phase 2
Completed
91 enrolled
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
ClinAssess · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the safety of lenalidomide and markers for disease progression in the treatment of IPSS low- or intermediate-1 risk MDS with isolated del5q.
Timeline
- Start
- 2010-03-26
- Primary completion
- 2018-05-24
- Completion
- 2018-05-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenalidomide | Other / unclassified | 10 mg | — |